Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies
Risankizumab 与克罗恩病患者生物标志物正常化相关:来自 3 期 ADVANCE、MOTIVATE 和 FORTIFY 研究的结果
期刊:Journal of Crohns & Colitis
影响因子:8.7
doi:10.1093/ecco-jcc/jjae164
Atreya, Raja; Ferrante, Marc; Panaccione, Remo; Feagan, Brian; Shchukina, Oksana; Jairath, Vipul; Rieder, Florian; Hisamatsu, Tadakazu; Siegmund, Britta; Kligys, Kristina; Song, Alexandra; Zambrano, Javier; Mallick, Madhuja; Zhang, Yafei; Armuzzi, Alessandro; D'Haens, Geert